Summary
Project Summary/Abstract Prostate cancer is a leading cause of cancer-related death in men. Novel technologies can improve access to high-quality care—particularly for patients at increased risk of aggressive disease or living in areas with a high prostate cancer burden. Current diagnostic methods, including PSA testing and biopsy, are often imprecise, leading to underdiagnosis and misclassification of disease severity. To address this, we propose a novel, non-invasive imaging modality using molecular chemical exchange saturation transfer (CEST) MRI on standard 3T scanners, combined with a m
